Picture of Vivoryon Therapeutics NV logo

VVY Vivoryon Therapeutics NV Share Price

0.000.00%
nl flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-94.09%
3m-93.82%
6m-95.78%
1yr-96.87%
Volume Change (%)
10d/3m+49.66%
Price vs... (%)
52w High-97.21%
50d MA-91.33%
200d MA-94.2%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-61.38%
Return on Equity-78.74%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Vivoryon Therapeutics NV EPS forecast chart

Profile Summary

Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the treatment of Alzheimer’s disease (AD) and other diseases with high medical need like Cancer and Fibrosis. The Company is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    June 30th, 2023
    Incorporated
    January 1st, 1970
    Public Since
    October 27th, 2014
    No. of Employees
    17
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    nl flag iconEuronext - Amsterdam
    Shares in Issue
    25,961,892

    VVY Share Price Performance

    Upcoming Events for VVY

    Q4 2023 Vivoryon Therapeutics NV Earnings Release

    Q1 2024 Vivoryon Therapeutics NV Earnings Release

    Vivoryon Therapeutics NV Annual Shareholders Meeting

    Similar to VVY

    Picture of BenevolentAI SA logo

    BenevolentAI SA

    nl flag iconEuronext - Amsterdam

    Picture of Galapagos NV logo

    Galapagos NV

    nl flag iconEuronext - Amsterdam

    Picture of Themis Bioscience BV logo

    Themis Bioscience BV

    nl flag iconEuronext - Amsterdam

    FAQ